platoseedplatoseed
Cancer tests based on whole genome and transcriptome data.
Isabl has developed software that can analyze the entire genome of cancer patients. Today, when people get cancer, they get a genetic test of their tumor that analyzes only a few possible mutations. With Isabl, you run the tumor through an Illumina sequencer and get the whole genome, then our software is able to analyze all the mutations. Our breakthrough technology provides unprecedented clarity into tumor biology to aid treatment planning. This opens up opportunities for precision diagnostics, disease surveillance and biomarker discovery.
Isabl offers a comprehensive molecular test for oncology that analyzes the entire tumor genome and transcriptome to identify cancer-associated mutations beyond panel-based tests. The company positions its technology as enabling more complete biomarker discovery and diagnostics for all cancer patients, including FDA Breakthrough Device Designation recognition.
Isabl analyzes 100% of the tumor genome and transcriptome to reveal relevant cancer-associated mutations in every sample, enabling comprehensive biomarker discovery and improved diagnosis. The product appears to be a WGTS SaaS offering aimed at enabling full-genome and transcriptome testing for oncology, with a focus on clinical implementation of genomic technologies.
Who it’s for: Oncology clinics, cancer centers, molecular diagnostics laboratories, and research institutions seeking comprehensive genomic profiling for cancer patients
funded by venture firms (Two Sigma Ventures, Y Combinator, BoxOne Ventures) and a spinoff from Memorial Sloan Kettering, with FDA Breakthrough Device Designation
Using CRISPR to find treatments for cancer and inflammation
Our tests help eradicate cancer by telling doctors whether they got…
